YOLFTbeta
Paxman AB

Paxman AB

PAX · ST · Healthcare / Medical Devices

67.50SEK+5.00 (+8.00%)

Price History

Full chart

Market Stats

Previous Close62.50
Open62.50
Day Range62.50 – 68.90
52-Week Range41.00 – 70.20
Volume53.27K
Market Cap1.54B
P/E (TTM)0.00
Forward P/E45.25
EPS-0.23
Dividend Yield0.00%
Beta0.48
50-Day Avg54.19
200-Day Avg50.92

About

Paxman AB (publ), together with its subsidiaries, provides cryotherapy solutions in the United Kingdom, Europe, North and South America, Oceania, and Asia. The company offers Paxman scalp cooling system, a mechanized form of scalp cooling for the prevention of chemotherapy-induced alopecia. It also engages in the development of a medical cryocompression device for the prevention of chemotherapy-induced peripheral neuropathy. The company was founded in 1996 and is based in Karlshamn, Sweden.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Richard Paxman O.B.E.
  • Employees151
  • HeadquartersPirgatan 13, Karlshamn, Sweden, 374 35, Sweden
  • Websitehttps://paxmanscalpcooling.com

Leadership

  • Mr. Richard Paxman O.B.E.CEO & Director · b. 1983
  • Ms. Emelie GustafssonChief Financial Officer · b. 1980
  • Ms. Alexandra SheldrakeHead of Operations · b. 1985
  • Dr. Simon TaylorTechnical Manager
  • Ms. Louise Aspey-SmithHead of Brand & Marketing Manager
  • Ms. Liza HirstEA to CEO & Head of HR · b. 1974
  • Ms. Claire PaxmanHead of Clinical Practice & Education · b. 1978
  • Mr. Patrick BurkeHead of Research and Development · b. 1959
  • Ms. Emma ThornhillGroup Finance Director · b. 1985
  • Mr. Stuart RowlingHead of UK Sales & Training · b. 1982

Financials

Income Statement

Currency: SEK2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue24.79M31.33M58.02M85.28M78.05M96.20M156.75M210.12M253.01M313.35M
Growth (%)-+26.42%+85.19%+46.97%-8.47%+23.25%+62.93%+34.05%+20.41%+23.85%
Cost of Revenue6.90M6.02M12.55M21.24M27.36M31.68M55.31M63.70M77.59M104.53M
Gross Profit17.89M25.31M45.48M64.04M50.69M64.52M101.44M146.42M175.42M208.81M
Gross Margin72.17%80.78%78.38%75.09%64.94%67.07%64.71%69.68%69.33%66.64%
Operating Expense15.53M32.10M50.26M65.33M62.38M75.09M102.65M133.80M141.91M204.55M
Operating Income2.35M-6.80M-4.78M-1.29M-11.69M-10.57M-1.22M12.62M33.51M4.26M
Operating Margin9.49%-21.69%-8.24%-1.52%-14.98%-10.99%-0.78%6.01%13.24%1.36%
EBITDA--5.20M-95.00K5.79M-2.60M1.25M16.18M31.23M49.73M28.46M
EBITDA Margin--16.58%-0.16%6.79%-3.33%1.29%10.32%14.86%19.65%9.08%
Net Income2.31M-6.72M-7.10M2.76M-19.19M-12.78M-10.32M8.33M40.20M-16.71M
Net Income Margin9.30%-21.46%-12.24%3.23%-24.58%-13.28%-6.59%3.96%15.89%-5.33%
R&D-755.00K1.12M1.31M1.55M1.65M2.02M2.15M--
R&D as % of Total Revenue-2.41%1.94%1.54%1.99%1.72%1.29%1.02%--
Interest Expense060.00K382.00K1.38M8.42M2.10M7.35M4.66M1.15M995.00K
Interest Expense % of Total Revenue0.00%0.19%0.66%1.62%10.79%2.18%4.69%2.22%0.45%0.32%

Balance Sheet

Currency: SEK2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets22.00M45.61M55.74M84.97M77.01M166.34M173.96M167.12M227.23M479.11M
Total Liabilities12.54M12.84M30.34M56.61M66.12M40.59M59.76M44.51M63.24M73.95M
Total Equity9.46M32.77M25.39M28.36M10.89M125.75M114.20M122.62M163.99M405.16M
Cash494.00K8.36M448.00K1.60M3.58M72.27M38.09M24.98M40.31M120.83M
Total Debt-2.76M12.78M31.45M48.23M17.15M16.98M13.57M14.29M13.01M
Net Debt--5.60M12.33M29.85M44.65M-55.11M-21.11M-11.41M-26.02M-107.83M

Cash Flow

Currency: SEK2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-7.13M400.00K3.31M-8.48M-4.14M2.69M15.63M39.10M7.39M
Investing Cash Flow-11.55M-18.32M-20.83M-6.32M-24.45M-36.69M-25.33M-24.50M-33.51M
Financing Cash Flow27.53M10.02M18.68M16.78M97.28M-169.00K-3.41M721.00K108.83M
Capital Expenditure12.53M18.69M20.83M6.32M23.80M35.69M25.33M23.11M23.47M
Free Cash Flow-19.66M-18.29M-17.52M-14.80M-27.94M-33.01M-9.70M15.99M-16.09M
FCF to OCF275.65%-4573.50%-530.17%174.49%674.37%-1228.82%-62.03%40.89%-217.77%

Earnings

Report DateJun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Nov 20, 2020Feb 26, 2021May 26, 2021Aug 27, 2021Nov 19, 2021Feb 25, 2022Mar 31, 2022Jun 30, 2022Sep 30, 2022Feb 24, 2023May 24, 2023Aug 24, 2023Nov 17, 2023Feb 23, 2024May 23, 2024Aug 21, 2024Nov 13, 2024Feb 19, 2025May 16, 2025Aug 20, 2025Nov 14, 2025Feb 27, 2026May 21, 2026Aug 21, 2026
EPS Estimate----------------------0.30-0.20-0.200.500.200.300.600.60-0.100.00-0.10-
EPS Actual0.06-0.16-0.38-0.10-0.05-0.02-0.27-0.030.020.050.130.16-0.40-0.26-0.69-0.22-0.31-0.30-0.07-0.330.030.24-0.51-0.130.270.39-0.090.690.520.260.64-0.29-0.140.050.120.220.11
Surprise-----------------------270.00%35.00%-95.00%-117.32%245.00%73.33%-56.67%6.67%--240.00%--120.00%-
Timing--------------Pre-marketPre-marketPre-marketPre-marketAfter-hours---Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap1.54B
Enterprise Value1.32B
Trailing P/E0.00
Forward P/E45.25
Price / Sales4.21
Price / Book3.40
EPS-0.23
Book Value17.91
Revenue (TTM)365.91M
Gross Profit (TTM)234.51M
EBITDA37.51M
Profit Margin-1.54%
Operating Margin3.65%
Return on Equity-1.30%
Return on Assets0.19%
Shares Outstanding23.27M
Shares Float16.62M
Beta0.48
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%